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FAHN/SPG35: a narrow phenotypic spectrum
across disease classifications
Tim W. Rattay,1,2 Tobias Lindig,3 Jonathan Baets,4,5,6 Katrien Smets,4,5,6
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Sarah Wiethoff,1,2 Jennifer Reichbauer,1 Marion Do¨bler-Neumann,10
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Alexander Mu¨nchau,13 Bernd Wilken,14 Marc Janauschek,15 Anne-Katrin Giese,16
Jan L. De Bleecker,17 Els Ortibus,18 Martine Debyser,19 Adolfo Lopez de Munain,20,21
Aurora Pujol,22,23,24 Maria Teresa Bassi,25 Maria Grazia D’Angelo,26 Peter De Jonghe,4,5,6
Stephan Zu¨chner,27,28 Peter Bauer,7,29 Ludger Scho¨ls1,2 and Rebecca Schu¨le1,2
The endoplasmic reticulum enzyme fatty acid 2-hydroxylase (FA2H) plays a major role in the formation of 2-hydroxy glyco-
sphingolipids, main components of myelin. FA2H deﬁciency in mice leads to severe central demyelination and axon loss. In
humans it has been associated with phenotypes from the neurodegeneration with brain iron accumulation (fatty acid hydroxy-
lase-associated neurodegeneration, FAHN), hereditary spastic paraplegia (HSP type SPG35) and leukodystrophy (leukodystrophy
with spasticity and dystonia) spectrum. We performed an in-depth clinical and retrospective neurophysiological and imaging study
in a cohort of 19 cases with biallelic FA2H mutations. FAHN/SPG35 manifests with early childhood onset predominantly lower
limb spastic tetraparesis and truncal instability, dysarthria, dysphagia, cerebellar ataxia, and cognitive deﬁcits, often accompanied
by exotropia and movement disorders. The disease is rapidly progressive with loss of ambulation after a median of 7 years after
disease onset and demonstrates little interindividual variability. The hair of FAHN/SPG35 patients shows a bristle-like appearance;
scanning electron microscopy of patient hair shafts reveals deformities (longitudinal grooves) as well as plaque-like adhesions to the
hair, likely caused by an abnormal sebum composition also described in a mouse model of FA2H deﬁciency. Characteristic imaging
features of FAHN/SPG35 can be summarized by the ‘WHAT’ acronym: white matter changes, hypointensity of the globus pallidus,
ponto-cerebellar atrophy, and thin corpus callosum. At least three of four imaging features are present in 85% of FA2H mutation
carriers. Here, we report the ﬁrst systematic, large cohort study in FAHN/SPG35 and determine the phenotypic spectrum, deﬁne
the disease course and identify clinical and imaging biomarkers.
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Introduction
Disturbances in sphingolipid metabolism have been impli-
cated in a growing number of neurological diseases, includ-
ing Parkinson’s disease, epilepsy, hereditary neuropathy,
hereditary spastic paraplegia, and ataxia (reviewed in
Astudillo et al., 2015). The endoplasmic reticulum
enzyme fatty acid 2-hydroxylase, encoded by the FA2H
gene, plays a major role in the formation of 2-hydroxy
sphingolipids from ceramide (Maldonado et al., 2008).
More than half of the galactolipids in myelin are 2-hydro-
xylated (Raghavan and Kanfer, 1972). Loss of FA2H func-
tion in mice leads to severe demyelination of optic nerves
and the spinal cord (Potter et al., 2011). These changes are
accompanied by pronounced axonal loss as well as altered
size and distribution of Purkinje neurons in aged mice while
myelination of peripheral nerves is relatively preserved.
Phenotypically, Fa2h/ mice display deﬁcits in motor co-
ordination, spatial memory, and learning (Potter et al.,
2011).
In humans, autosomal recessive mutations in FA2H have
been associated with three clinically deﬁned disease entities
with overlapping phenotypic spectra: (i) leukodystrophy
with spasticity and dystonia (OMIM #612319) (Uchida
et al., 2007; Edvardson et al., 2008); (ii) fatty acid
hydroxylase-associated neurodegeneration (FAHN, OMIM
#611026) (Kruer et al., 2010), a rare subtype of neurode-
generation with brain iron accumulation (NBIA); and (iii)
hereditary spastic paraplegia (HSP) type SPG35 (OMIM
#612319) (Dick et al., 2010). Taken together, 65 cases
with FA2H mutations from 31 families have been pub-
lished so far, carrying 40 distinct mutations. Standardized
phenotypic descriptions and systematic analysis of the
phenotypic spectrum in larger cohorts are lacking since
prior publications contained no more than three families
(Edvardson et al., 2008) or are limited to literature
review of published cases (Mari et al., 2018).
Here, we report the ﬁrst systematic, large cohort study in
FAHN/SPG35 to determine the phenotypic spectrum, deﬁne
the disease course and identify clinical biomarkers as well
as conﬁrm and specify imaging characteristics.
Materials and methods
Clinical characterization
All cases received a detailed clinical examination by a move-
ment disorder specialist including standardized rating of dis-
ease severity using the spastic paraplegia rating scale (SPRS)
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(Schule et al., 2006). The majority of cases were re-evaluated
clinically after their genetic diagnosis had been made.
Neurophysiological characterization included motor evoked
potentials, sensory evoked potentials, and nerve conduction
studies; hereby, retrospective data were used.
Unless stated otherwise (Supplementary Table 1), no formal
neurophysiological testing was available for the majority of
cases. Cognitive deﬁcits were evaluated clinically as well as
based on clinical history. Cognitive decline was noted when
loss of cognitive abilities was reported over time.
All subjects included in the study gave their written informed
consent according to protocols approved by the respective in-
stitutional human ethics review boards.
MRI
Retrospective routine MRI data from 13 patients were col-
lected from eight different sites and was re-evaluated by an
experienced neuroradiologist (T.L.). As MRIs were obtained
at different time points and clinical centres and not within a
study setting, no harmonized MRI protocol was used and ﬁeld
strengths varied between scanners. To assess midbrain and
pons atrophy, the area of the midbrain and pons was mea-
sured on mid-sagittal MRI; an area smaller than 88 mm2 or
417 mm2 [average 2 standard deviations as described in Oba
et al. (2005)] was regarded as midbrain or pons atrophy,
respectively.
Genetic analyses
FA2H mutations were detected by different genetic approaches
including Sanger sequencing, a next generation sequencing
(NGS)-based HSP gene panel and whole exome sequencing
(see ‘Results’ section for more details). All sequence abnorm-
alities were conﬁrmed by Sanger sequencing. Mutated
positions were annotated in reference to transcript
ENST00000219368.
We used PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/),
SIFT (http://sift.bii.a-star.edu.sg) and MutationTaster (http://
www.mutationtaster.org/) to predict the impact of missense
mutations on the structure and function of the protein
(Table 1). The ExAC Browser and Exome Variant Server
(EVS) data on minor allele frequency (MAF) were retrieved
on 4 September 2018. We recently published genetic informa-
tion, focusing on an unusual inheritance pattern of uniparental
disomy, about Families F1, F8, F10, and F13 (Soehn et al.,
2016).
Scanning electron microscopy of hair
shafts
Hair samples were mounted to aluminium sample holders with
Leit-Tabs G3347 (Plano). The probes were sputtered with gold
(15-nm thickness) prior to imaging. Pictures were taken at a
magniﬁcation of 250 by using secondary electrons with an
S800 scanning electron microscope (Hitachi). In Patient F8,
pictures were taken using a CS2 scanning electron microscope
(CamScan).
Statistics
Descriptive statistics and survival analysis (Kaplan-Meier ana-
lysis) were performed using SPSS v25 for Windows (IBM,
Armonk, NY).
Data availability
The authors conﬁrm that the data supporting the ﬁndings of
this study are available within the article and its
Supplementary material. Raw data regarding human subjects
(e.g. genetic raw data, MRI datasets) are not shared freely to
protect the privacy of the human subjects involved in this
study; no consent for open sharing has been obtained.
Results
Genetic findings
Screening of a large cohort of movement disorder
cases
To appraise the clinical spectrum of FA2H mutations, we
screened exome data available from a large cohort of 2774
cases from 1482 families with various motor neuron and
movement disorder phenotypes and family history compat-
ible with autosomal recessive disease for mutations in
FA2H [Genesis database: www.genesis-app.com (Gonzalez
et al., 2015)]. Phenotypes included the following (numbers
based on families): amyotrophic lateral sclerosis (n = 620),
HSP (n = 139; pure/complicated 45/94), ataxia (n = 62),
dystonia (n = 9), Parkinson’s syndrome (n = 67), neuromus-
cular diseases (n = 354), epileptic encephalopathy (n = 115),
mitochondrial disease (n = 84), and others (n = 32).
This approach uncovered nine families with homozygous
or compound heterozygous FA2H mutations (Families F1–
F6, F11, 12 and F14; Supplementary Table 1). Although
we included a wide spectrum of phenotypes in the screen-
ing, all positive cases were phenotypically classiﬁed as com-
plicated HSP, indicating a strong enrichment of FA2H
mutations in this phenotype.
Identification of additional FA2H families
We then reached out to colleagues to collect further
families with FA2H mutations. Using this approach, we
identiﬁed an additional seven families. In Families F7,
F13, F15 and F16, whole exome sequencing was per-
formed. Families F8 and F10 were examined using an
NGS-based gene panel containing 98 spasticity associated
genes at the University of Tu¨bingen (technical details in
Synofzik et al., 2014b). The index of Family F9 was
screened for mutations in FA2H by Sanger sequencing.
Altogether, we identiﬁed 19 FA2H cases in 16 families.
Evaluation of mutations
The 16 FA2H families we report here carry 19 distinct FA2H
mutations (Table 1). As loss-of-function is the established
mutation mechanism in FA2H (Edvardson et al., 2008;
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Dick et al., 2010) we considered all six truncating muta-
tions (four deletions leading to a shift in the reading frame
and two nonsense mutations) to be pathogenic. Among the
13 missense mutations we identiﬁed, four have been asso-
ciated with an FAHN/SPG35 phenotype previously
[c.460C4T, p.R154C (Kruer et al., 2010; Kara et al.,
2016); c.620C4T, p.T207M (Pensato et al., 2014);
c.704G4A, p.R235H (Magariello et al., 2017),
c.968C4T, p.P323L (Rupps et al., 2013)]. The remaining
nine were either absent in public databases (n = 5) or ex-
ceedingly rare (MAF5 0.1%, n = 4) (EVS6500, ExAC
browser, accessed on 9 April 2018). All but one
(c.859T4C, p.C287R) of the novel missense variants
were highly conserved (GERP, PhastCons) and at least
two of three prediction algorithms (PolyPhen-2, SIFT,
MutationTaster) predicted them to be likely pathogenic.
The only exception was the variant c.859T4C, p.C287R
observed in Family F7. This variant, located in the sterol
desaturase domain, is absent in public databases (EVS and
ExAC) as well as in our in-house database containing
26 000 alleles; the affected amino acid is only weakly
conserved and predicted to be tolerated in all three in
silico prediction algorithms we used. In Family F7 this vari-
ant is compound heterozygous with c.704G4A, R235H, a
previously-described strong missense variant (Magariello
et al., 2017) also identiﬁed in Family F6 that affects an
amino acid implicated in FAHN/SPG35 previously
(c.703C4T, p.R235C; Dick et al., 2010).
In 12 of 16 families, DNA of both parents was available,
allowing segregation analysis, in one family (Family F11),
DNA of one parent was available and in three families,
parental DNA could not be obtained (Families F2, F6
and F9). Segregation analysis revealed uniparental disomy
in four families (Families F1, F8, F10 and F13; reported in
Soehn et al., 2016) and identiﬁed a de novo mutation
(c.460C4T, p.P154C), compound heterozygous with a
paternally inherited missense mutation in Family F16.
The remaining mutations were conﬁrmed to be either
homozygous or compound heterozygous, as expected
(Supplementary Fig. 1). Together with this study the
number of published FA2H mutations increased to a total
of 43 (Fig. 1 and Supplementary Table 2). The vast
majority of FA2H mutations are private and only eight
mutations occur in more than one family (c.21del,
p.A8Pfs*91; c.160_169del, p.A54Tfs*42; c.232G4A,
p.E78K; c.460C4T, p.P154C; c.509_510delAC, p.Y170*;
c.620C4T, p.T207M; c.704G4A, p.R235H; c.968C4T,
p.P323L).
Description of the phenotype
Detailed clinical data on 19 cases with FAHN/SPG35 from
16 families are provided in Supplementary Table 1. Gait
problems started almost invariably in early childhood at a
median age of 4 years [interquartile range (IQR) 3–4.5
years]; all but two individuals (Patient F9, age at onset
20 years and Patient F14, age at onset 10 years) showed
symptoms before the age of 5 years. Patients became wheel-
chair dependent after median disease duration of 7 years
(IQR 3–12 years) (Kaplan-Meier analysis). At the time of
examination (median disease duration 5.5 years), all cases
had a spastic tetraparesis with lower limb predominance,
and varying degrees of truncal instability (Fig. 2A). Mild
cognitive deﬁcits were noted from childhood on in the ma-
jority of cases (93%) and were considered to be progressive
(information provided by parents based on loss of cognitive
abilities over time) in all but two cases. Oculomotor
abnormalities with cerebellar characteristics—as determined
by clinical examination—were also present in all cases: the
most frequent feature was saccadic pursuit (81%), accom-
panied by gaze-evoked nystagmus in 27%. Horizontal sac-
cades were markedly slowed in 57%. Furthermore, 60% of
the cases had exotropia in the absence of visual
impairment.
Limb ataxia was present in 71%. Dysarthria was almost
universally present (88%) and was clinically classiﬁed as
pseudobulbar and/or cerebellar (Darley et al., 1969).
Three patients became anarthric during the course of dis-
ease (420 years after disease onset). Dysphagia was a fre-
quent ﬁnding (71%). Movement disorders were present in
50% of cases with rigidity and dystonia (both present in
four cases) being most common. One patient presented
with resting tremor. Sensory involvement was mild if pre-
sent at all. Other signs and symptoms included optic atro-
phy (31%) and seizures (focal semiology in two cases, one
case with febrile seizures).
Neurophysiological examination of the CNS showed
absent motor evoked potentials (MEP) to the lower limbs
in 57% (performed in seven individuals) and normal cen-
tral conduction times in the remaining cases, indicating a
primarily axonal type of damage. Sensory evoked potentials
were abnormal in two of nine cases (22%). Thirty-eight per
cent of cases had abnormal visually evoked potentials
(VEP) with prolonged P100 latency in three of eight
cases. Peripheral neuropathy was present in 27% (3/11)
of cases (Supplementary Table 1). This analysis was per-
formed on retrospective data.
Since four uniparental disomy (UPD) cases are included
in this series we also looked for imprinting phenotypes of
chromosome 16 with intrauterine growth restriction
(mUPD16) and/or alveolar capillary dysplasia with mis-
alignment of pulmonary veins (ACDMPV) (pUPD16/mat
del 16q24). However, no case was reported to be under-
weight at birth or had any early pulmonary problems.
Genotype-phenotype correlation
Genetically, missense and truncating mutations in FA2H
have been reported to be pathogenic. When considering
all published and the novel mutations reported here, there
are 50 distinct mutations in FA2H that have been asso-
ciated with a FAHN/SPG35 phenotype. These include 14
truncating (frameshift, splice, nonsense) and 36 non-trun-
cating (missense, inframe deletion) changes. The latter,
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thus, are the predominant mutation type in FA2H (Fig. 1).
As suggested previously, missense mutations in FA2H pref-
erentially target one of the two known functional domains
of FA2H (Edvardson et al., 2008). Among all known 33
missense changes, 10 are located in the cytochrome B5-like
heme-binding domain (codons 15–85, encompassing 8.8%
of the protein) and 17 in the sterol desaturase domain
(codons 210–367, 19.6% of the protein), while only six
mutations are located outside of these known domains
(71.6% of the protein). Detailed comparative analysis of
the phenotype (Supplementary Table 2) revealed no appar-
ent genotype phenotype correlations depending on the mu-
tation type present.
Imaging findings
We re-evaluated retrospective MRI data from 13 FA2H
mutation carriers. In all cases, T2 hyperintense white
matter abnormalities were found in the periventricular
white matter with parietal predominance. The globus
Figure 2 Phenotypic spectrum of FAHN/SPG35 and relevant differential diagnosis. (A) The phenotypic spectrum of FAHN/SPG35
with prevalence rates (in per cent) of specific features. MRI findings are coloured in yellow, clinical signs and symptoms are highlighted in blue.
(B) The FAHN/SPG35 phenotype overlaps the clinical presentation of a range of movement disorders. Main differential diagnoses of FAHN/
SPG35 from the spectrum of hereditary spastic paraplegias (cHSPs), NBIA and giant axonal neuropathy that shares some features of the
ultrastructural hair phenotypes with FAHN/SPG35 are depicted. Discriminating features are highlighted. CoPAN = COASY protein-associated
neurodegeneration; GAN = giant axonal neuropathy; MPAN = mitochondrial membrane protein-associated neurodegeneration.
Figure 1 Mutation spectrum in FA2H/SPG35. Structure of the FA2H coding sequence (NCBI Reference Sequence: NM_024306.4) is shown
with numbered exons 1–7 in alternating grey shades. For each variant, cDNA change and the presumed effect on the resulting protein are given
(where possible). For changes observed in this study, the family number is given in square brackets and turquoise font; the letter ‘h’ indicates
(compound)-heterozygous occurrence. Missense mutations (black) and inframe deletions (brown) are listed above, truncating mutations including
nonsense mutations (orange), frameshift insertions or deletions (purple) and splice changes (green) below the graph. The cDNA is overlain by the
two known functional protein domains (cytochrome B5-like heme-binding domain and sterol desaturase domain), indicated as black boxes.
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Figure 3 MRI findings in FAHN/SPG35. (A) The most frequent imaging findings in FAHN/SPG35 can be summarized by the acronym
‘WHAT’ (i) white matter changes (asterisk in VI–IX and XI); (ii) hypointensity of the globus pallidus in T2/T2-FLAIR/T2*/SWI (hash symbol in X–
XII); (iii) ponto-cerebellar atrophy (dagger and arrowhead in I–VI); and (iv) thin corpus callosum. Sagittal images show a general corpus callosum
thinning predominantly affecting the (dorsal) body (double dagger in I and IV). Pontine atrophy (dagger symbol in I–IV) was measured on
midsagittal MRI (II) with the upper border a line (‘a’) through the superior pontine notch and the inferior edge of the quadrigeminal plate, and with
the lower border (‘b’) parallel to the upper border and through the inferior pontine notch. Ponto (dagger)- cerebellar (arrowhead) atrophy is
depicted in III with widening of the fourth ventricle, affecting the upper vermis and the hemispheres (I, III-VI). Predominantly mild supratentorial
atrophy with a focus on the parietal lobe is depicted in V and IX (arrows). Periventricular white matter abnormalities are shown on T2-FLAIR
images most affecting the parietal white matter (asterisk in VI–IX and XII). Hypointense signal of the globus pallidus associated with iron
accumulation is shown on T2, T2-FLAIR and susceptibility weighted images (hash symbol in X–XII). (B) Venn diagram depicting the occurrence of
MRI features contributing to the ‘WHAT’ imaging phenotype. In 85% of cases (11/13), at least three of four ‘WHAT’ features were found, in 54%
(7/13), all four features were present.
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pallidus showed an overall mild T2/T2-FLAIR/SWI/T2*
hypointense signal in 77%. Mild to moderate cerebellar
atrophy of the vermis and the hemispheres was seen in
85% of patients. In 62% of patients, there was supraten-
torial atrophy, which was mild and predominantly parietal
in most, but global in older cases. A substantial atrophy of
the pons could be demonstrated in 85%. Another common
MRI feature in FAHN/SPG35 was a thin corpus callosum
(69%) ranging from focal thinning of the dorsal body to a
general thinning (Supplementary Table 1 and Fig. 3A).
Hair abnormalities
Several patients presented with unusually bristly hair that
differed from the hair in other family members. Often the
hair was kept short by patients or caregivers due to the
frizzy appearance (Fig. 4A). As FA2H has a known func-
tion in keratinocytes [responsible for epidermal permeabil-
ity barrier homeostasis (Uchida et al., 2007)] and sebaceous
glands [required for synthesis of 2-hydroxylated glucosyl-
ceramide and a fraction of type II wax diesters (Maier
et al., 2011)], we decided to perform scanning electron mi-
croscopy of hair shafts. Between 10 and 16 hair shafts in
each of four patients (Patients F1, F2, F7 and F8) were
examined. Strikingly, hair shafts of all four patients demon-
strated subtle to pronounced longitudinal grooves (Fig.
4C); hereby, between 20 and 100% of hair shafts in each
patient were affected by this abnormality. No longitudinal
grooves were observed in control hair samples.
Three of four patients also had adhesive plaques on their
hair shafts (Fig. 4D). Two distinct plaque formations could
be observed: small roundish shaped plaques and larger
chunky plaque formations (Fig. 4G and H).
Discussion
FA2H mutations have been associated with three distinct
disease categories in the past: neurodegeneration with brain
iron accumulation, leukodystrophy, and hereditary spastic
paraplegias. Does this indicate an (unusually) large pheno-
typic variability of FA2H disease or reveal the challenge to
classify phenotypically complex diseases unambiguously?
Our standardized clinical workup of a large cohort of 19
FAHN/SPG35 patients and the high degree of congruence
with previously published studies (Edvardson et al., 2008;
Dick et al., 2010; Kruer et al., 2010; Mari et al., 2018)
supports the latter. First, a large phenotypic variability of
FA2H mutations is unlikely given that we screened 42700
cases with a broad range of autosomal recessive movement
disorder and motor neuron phenotypes, and identiﬁed bial-
lelic mutations in FA2H exclusively in patients diagnostic-
ally labelled as HSP. Second, the clinical phenotype
observed in our FAHN/SPG35 cases was rather uniform
Figure 4 Hair analysis: macroscopy and electron microscopic finding. (A) Photograph of Patient F8 with bristle like hair structure,
which is kept short by the caregivers. (B–H) Scanning electron microscopy images at 250 (B–F) and 400 (G and H) of representative hair
shafts. (B) Healthy control hair. (C and D) Patient F1 exemplary hair shafts present with longitudinal grooves in C and adhesive plaques in D.
(E) Hair of Patient F2 shows longitudinal grooves but no adhesive plaques. (F) Longitudinal grooves in hair of Patient F7. (G and H) Hair of Patient
F8 shows longitudinal grooves and adhesive plaques with a chunky appearance.
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across the cohort with lower limb predominant spastic tet-
raparesis accompanied by truncal instability, dysarthria,
dysphagia, cerebellar ataxia, and cognitive deﬁcits present
in 90% of cases. Other frequent symptoms, present in at
least half of all cases, were exotropia and movement dis-
orders, particularly dystonia, rigidity, or resting tremor.
The FAHN/SPG35 phenotype we were able to deduce
from our unbiased cohort conﬁrms ﬁndings from previous
smaller studies (Edvardson et al., 2008; Dick et al., 2010;
Kruer et al., 2010; Mari et al., 2018) that describe
very similar clinical characteristics of FAHN/SPG35.
Pathophysiologically, neurogenic exotropia is considered
to be a consequence of fastigial nucleus dysfunction
(Leigh and Zee, 2015) and thus part of the cerebellar syn-
drome seen in FAHN/SPG35. The age of onset spectrum
was narrow with an onset in early childhood (55 years) in
90% of cases and thus also supports a rather conserved
phenotype and disease manifestation, although later disease
manifestations rarely occur (Tonelli et al., 2012). These
features are compatible with and can even be considered
typical for each of the three disease categories FA2H mu-
tations have been associated with. Moreover, the categories
NBIA, leukodystrophy and HSP are not divisive, as the
former two are based on the non-exclusive and often over-
lapping presence of imaging ﬁndings while HSP is a clinical
classiﬁcation concept. We therefore suspect that the classi-
ﬁcation of patients with FA2H mutations may be primarily
inﬂuenced by the experience and background of the diag-
nosing clinician, probably modiﬁed by the individual sever-
ity of speciﬁc signs or symptoms in a given patient but
bears little systematic value. Similar observations have
been made for other genes associated with complex pheno-
types in recent years [e.g. PNPLA6 (Synofzik et al., 2014a),
ATP13A2 (Estrada-Cuzcano et al., 2017), POLR3A
(Minnerop et al., 2017), PLA2G6 (Synofzik and Gasser,
2017), and SPG7 (Synofzik and Schule, 2017)] and
prompts currently used classiﬁcation systems to be recon-
sidered (Marras et al., 2016; Schule, 2017).
Detailed phenotypic analysis of published cases as well as
the cases reported here revealed no association between
phenotype and mutation type. Recently, it has been sug-
gested that there may be some genotype-phenotype correl-
ation for speciﬁc missense variants in FA2H (Mari et al.,
2018); the study is, however, limited by the lack of stan-
dardized clinical assessment of the reported cases and ab-
sence of comprehensive criteria for the phenotypic
classiﬁcation [(i) leukoencephalopathy; (ii) spastic paraple-
gia; (iii) cerebellar and basal ganglia involvement] the au-
thors propose. Further prospective studies are therefore
needed to address this question.
Although rather uniform in itself, the phenotype asso-
ciated with FA2H mutations overlaps the clinical presenta-
tion of a number of hereditary movement disorders.
Compared to other HSPs the disease onset in FAHN/
SPG35 [median 4 versus 31 years in a genetically mixed
cohort of 4600 HSP patients (Schule et al., 2016)] is very
early and the progression decidedly faster with loss of
ambulation after a median of 7 years after disease onset
[compared to wheelchair dependency in one-quarter of pa-
tients with genetically mixed HSP after 37 years disease
duration (Schule et al., 2016)]. Among the HSPs, FA2H
mutation carriers show the largest overlap with SPG11,
SPG15, SPG48 (Pensato et al., 2014) and SPG78
(Estrada-Cuzcano et al., 2017). These HSPs share frequent
cognitive deﬁcits, cerebellar ataxia, and movement dis-
orders. However, frequency and severity of dysphagia in
FAHN/SPG35, which has prompted Rupps et al. (2013)
to coin the term ‘complete loss of oromotor control’ in
these patients, as well as the frequent occurrence of truncal
hypotonia and exotropia set FAHN/SPG35 apart from
SPG11, SPG15, and SPG48 (Kruer et al., 2012; Pensato
et al., 2014). Compared to SPG78, characterized by an
adult onset pyramidal-cerebellar syndrome with frequent
cognitive deﬁcits, parkinsonism, and axonal neuropathy
due to mutations in the ATP13A2 gene, the onset of
FAHN/SPG35 is considerably earlier and the typical
FA2H-associated imaging ﬁndings of a thin corpus callo-
sum and white matter changes are rarely seen in SPG78
(Estrada-Cuzcano et al., 2017).
In comparison to other subtypes of the NBIA spectrum,
extrapyramidal involvement, most commonly rigidity (four
patients) or dystonia (four patients), seems to be less
frequent and less pronounced at least in our cohort of
FAHN/SPG35 patients. Among the NBIAs, spasticity
can also be a prominent feature especially in mitochon-
drial membrane protein-associated neurodegeneration
(MPAN) and COASY protein-associated neurodegeneration
(CoPAN) (Hogarth, 2015). Prominent parkinsonism and
oromandibular dystonia in CoPAN may help to differenti-
ate it from FAHN/SPG35 whereas MPAN frequently pre-
sents with optic atrophy and sometimes psychiatric features
(Hogarth, 2015). Figure 2B offers a guideline for clinical
and imaging differential diagnosis among these overlapping
disease entities.
A unique clinical feature of FA2H disease appears to be
the wiry hair that elicits the association of bristles when
being touched. Interestingly, a fur phenotype was also
described for Fa2h knock-out mice (Maier et al., 2011).
Here, emergence of hair from sebaceous glands is believed
to be blocked by sebum plugs that are formed by highly
viscous sebum trapped in the dilated hair canals and
released en bloc from the sebaceous gland. These changes
result in delayed fur development with a less soft and
glossy appearance than in wild-type littermates (Maier
et al., 2011). Similar sebum plugs, although not shown in
our patients directly, might explain the longitudinal
grooves and adhesive plaques that were visible ultrastruc-
turally. Sebum trapped in the hair canal might lead to de-
formation of emerging hair shafts and the adhesive plaques
might correspond to additional sebum material sticking to
the hair shafts. Longitudinal grooves have also been
described in the curly hair of patients with giant axonal
neuropathy (Treiber-Held et al., 1994). In FAHN/SPG35,
however, the hair does not seem to have the same
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propensity to form curls as in giant axonal neuropathy.
Since scanning electron microscopy is widely available,
hair may be used as an easily accessible biomarker that
can guide towards a diagnosis of FAHN/SPG35.
Considering the extent and frequency of white matter
changes present we were surprised to ﬁnd abnormal
evoked potentials (motor: 57% abnormal; sensory: 22%
abnormal; visual: 38% abnormal) in only a subset of
cases. The validity of our ﬁndings, however, is limited be-
cause of the retrospective nature of the available neuro-
physiological data, and the lack of standardization
between the diagnostic laboratories.
The MRI phenotype in our cohort of FAHN/SPG35 pa-
tients was strikingly uniform. The most common ﬁndings
were white matter changes (100%), followed by cerebellar
atrophy (85%), pons atrophy (85%), overall mild T2/T2-
FLAIR/T2*/SWI hypointense signal of the pallidum (77%),
a thin corpus callosum (69%), and supratentorial atrophy
(62%). Interestingly, the very same MRI features have al-
ready been identiﬁed by Kruer et al. (2010) based on MRIs
obtained in two cases and review of the literature. In our
larger cohort we were now able to conﬁrm that these fea-
tures are indeed typical hallmarks of FAHN/SPG35. We
therefore suggest the term ‘WHAT’ to summarize the ima-
ging ﬁndings in FA2H disease, whereby each letter repre-
sents a common MRI feature: white matter changes,
hypointensity of the globus pallidus, ponto-cerebellar atro-
phy, and thin corpus callosum. Eighty-ﬁve per cent of pa-
tients had at least three of the WHAT features, in more
than half of the patients (54%), all four features were pre-
sent (Fig. 3B). The WHAT imaging phenotype therefore
might assist the clinical diagnosis of FAHN/SPG35 al-
though its sensitivity and speciﬁcity need to be determined
in larger prospective cohorts.
We were surprised to ﬁnd a high rate of patients with T2/
T2-FLAIR/T2*/SWI hypointense signal changes indicating
iron deposition in the globus pallidus (77%), as this con-
trasts with reports from Marelli et al. (2015). In a review of
several small case studies (33 FAHN/SPG35 patients in 11
studies) they report MRI indication of iron deposits in no
more than a third of cases. Several factors might contribute
to this discrepancy: First, the lack of consensus on the
extent of hypointense T2/T2* signals that are considered
physiological or outside physiological ranges, especially
when considering MRIs obtained using heterogeneous
protocols at different ﬁeld strengths may introduce bias in
MRI interpretation; this is of particular relevance for the
literature report by Marelli et al. (2015). The overall small
number of patients in whom T2* or susceptibility-weighted
imaging (SWI) sequences were performed and the lack of a
systematic and uniform MRI analysis across the heteroge-
neous studies reported by Marelli et al., may have led to an
underestimation of iron deposition in FAHN/SPG35.
Prospective studies using standardized MRI protocols and
scanners and preferably automated image analysis are ne-
cessary to overcome this bias. Second, lack of CT scans or
quantitative susceptibility mapping (QSM) did not allow us
to exclude basal ganglia calciﬁcations that thus might have
contributed to hypointense signals within the globus palli-
dus and thus may have led to an overestimation of iron
deposition in our retrospective analysis.
Brainstem atrophy has been described previously in
about two-thirds of FAHN/SPG35 patients (Marelli et al.,
2015). here, we used cross-sectional area quantiﬁcation to
characterize this feature further, which we observed at even
higher frequency (85%) in our cohort. Characteristically,
the volume of the pons is diminished in FAHN/SPG35
while the mesencephalon is comparably preserved.
Advanced MRI techniques such as diffusion tensor imaging
and voxel-based morphometry may help to identify ﬁbre
tracts associated with speciﬁc clinical signs such as exotro-
pia [e.g. dorsal visual pathway (Yan et al., 2010)] or iden-
tify additionally involved brain regions (in analogy to
Lindig et al., 2015).
Conclusions
Biallelic FA2H mutations cause a narrow phenotypic spec-
trum characterized by early-onset spastic tetraparesis, cere-
bellar ataxia, dysarthria, dysphagia and cognitive deﬁcits,
frequently accompanied by exotropia, and movement dis-
orders (dystonia, rigidity). Bristle-like hair, a clinical correl-
ate of ultrastructural changes of the hair shafts due to
altered sebum composition, are a tell-tale clinical sign.
Characteristic imaging features can be summarized by the
‘WHAT’ acronym: white matter changes, hypointensity of
the globus pallidus, ponto-cerebellar atrophy, and thin
corpus callosum.
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